相关实验视频

Updated: Jan 10, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

拉夫利祖马布和埃奎利祖马布抑制经典和替代补充途径

Lea Gerischer^1,2, Frauke Stascheit^1,2, Maximilian Mönch³

¹Department of Neurology With Experimental Neurology and Integrated Myasthenia Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.

Annals of clinical and translational neurology

|November 20, 2025

概括

替代途径活性 (AH50) 可能预测在接受ravulizumab.com的一般化肌痛性硬化症 (gMG) 患者的治疗反应. 较高的AH50水平与治疗效果减弱和早期症状复发相关,表明其作为生物标志物的潜力.

科学领域:

免疫学免疫学免疫学
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

一般化肌痛性肌痛症 (gMG) 是一种影响神经肌肉传播的自身免疫性疾病.
补充通路的激活在gMG病原发生过程中起作用.
目前的C5抑制剂,如eculizumab和ravulizumab针对这种途径.

研究的目的:

评估古典 (CH50) 和替代 (AH50) 补充通路活性作为gMG中的拉武利祖马布治疗的生物标志物.
为了比较补充活性监测与治疗药物监测eculizumab.
探索AH50在预测治疗反应和持续时间方面的作用.

主要方法:

在61名ACHR-ab阳性GMG患者的前性,探索性现实研究中.
在剂量结束时评估CH50和AH50水平,以及eculizumab/ravulizumab水平.
相关的实验室数据与患者报告的ravulizumab效应持续时间.

主要成果:

在剂量结束时,ravulizumab (5%) 与eculizumab (1%) 相比,AH50水平的抑制较小.
由于效果不足而停止使用拉武利祖马布的患者的AH50水平较高 (7%与5%相比).
81%的患者在8周间隔之前经历了拉武利祖马布效果的减弱;更高的AH50与更早的复发相关.

结论:

拉夫利祖马布和eculizumab在补充通路抑制方面可能在它们的剂量间隔之间有所不同.
升高的AH50水平可能表明RAVULIZUMAB的反应不佳和更快的消耗.
在大型多中心研究中需要进一步验证.

关键词:

补充抑制是补充的抑制.补充路径是补充路径.在此之前,Eculizumab也曾被使用过.肌痛性骨髓灰质炎 (Myasthenia Gravis) 是一个严重的疾病.拉维鲁兹马布的使用情况

更多相关视频

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Complement System

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...

Antibody Actions

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...